Advertising and Promotion Regulatory Affairs Conference

As artificial intelligence continues to evolve and rapidly expands, regulatory reviewers require new tools to evaluate AI technologies to identify regulatory compliance risks. The session will explore the benefits and risks of using generative AI for prescription drug marketing and how marketers can implement guardrails to protect HCP and consumer perceptions of their products, ensure user privacy, and configure generative AI systems to prevent non-compliant presentations of medical information. In addition, the panel will discuss the common regulatory risks presented by AI models including training bias, application of knowledge concepts, and personas. The panel will propose a structured methodology for regulatory reviewers to assess regulatory compliance risks and appropriateness of a given AI model or solution for prescription drug marketing.